Literature DB >> 3309751

Oxytocin during labor after previous cesarean section: results of a multicenter study.

B L Flamm1, J R Goings, N J Fuelberth, E Fischermann, C Jones, E Hersh.   

Abstract

The use of oxytocin for labor induction or augmentation in patients with previous cesarean delivery is controversial. This paper presents a series of 1776 patients allowed to labor after a previous cesarean section, of whom 485 (27%) were treated with oxytocin. When the patients who received oxytocin were compared with those who did not, no significant differences were found with respect to uterine rupture, maternal morbidity, fetal morbidity, or fetal mortality. We conclude that the judicious use of oxytocin is safe in the patient with a previous low transverse cesarean section.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3309751

Source DB:  PubMed          Journal:  Obstet Gynecol        ISSN: 0029-7844            Impact factor:   7.661


  4 in total

Review 1.  Systematic review of the incidence and consequences of uterine rupture in women with previous caesarean section.

Authors:  Jeanne-Marie Guise; Marian S McDonagh; Patricia Osterweil; Peggy Nygren; Benjamin K S Chan; Mark Helfand
Journal:  BMJ       Date:  2004-07-03

Review 2.  The use of oxytocin after a previous caesarean section--a review and report on a series.

Authors:  D Bider; G Barkai; H J Carp; S Mashiach
Journal:  Arch Gynecol Obstet       Date:  1990       Impact factor: 2.344

3.  Delivery after prior cesarean: maternal morbidity and mortality.

Authors:  Yvonne W Cheng; Karen B Eden; Nicole Marshall; Leonardo Pereira; Aaron B Caughey; Jeanne-Marie Guise
Journal:  Clin Perinatol       Date:  2011-06       Impact factor: 3.430

4.  Clinical interventions that influence vaginal birth after cesarean delivery rates: Systematic Review & Meta-Analysis.

Authors:  Aireen Wingert; Lisa Hartling; Meghan Sebastianski; Cydney Johnson; Robin Featherstone; Ben Vandermeer; R Douglas Wilson
Journal:  BMC Pregnancy Childbirth       Date:  2019-12-30       Impact factor: 3.007

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.